---
id: nccn-sclc-2025
title: "NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer"
short_title: "Small Cell Lung Cancer"
organization: National Comprehensive Cancer Network
country: United States
url: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1462
specialty: oncology
guideline_type: clinical-practice
evidence_system: nccn
conditions:
  - Small Cell Lung Cancer
  - SCLC
tags:
  - lung cancer
  - small cell
  - chemotherapy
  - immunotherapy
  - thoracic radiation
publication_date: 2025-01-10
previous_version_date: 2024-01-15
status: current
supersedes: nccn-sclc-2024
superseded_by: null
pdf_path: null
has_pdf: false
last_reviewed: 2025-01-01
---

## Scope

This guideline provides recommendations for the diagnosis, staging, and treatment of small cell lung cancer (SCLC).

## Key Recommendations

### Staging
- Limited-stage (LS): Confined to one hemithorax, can be encompassed in a radiation field
- Extensive-stage (ES): Disease beyond limited-stage definition

### Limited-Stage SCLC
**Standard Treatment:**
- Concurrent chemoradiation
- Platinum (cisplatin/carboplatin) + etoposide x 4 cycles
- Early-concurrent thoracic radiation (begin with cycle 1-2)
- Twice-daily radiation (45 Gy) or once-daily (66 Gy)

**Prophylactic Cranial Irradiation (PCI):**
- Recommended for patients achieving CR or good PR
- Reduces brain metastases and improves survival

### Extensive-Stage SCLC
**First-Line:**
- Platinum + etoposide + atezolizumab (IMpower133)
- Platinum + etoposide + durvalumab (CASPIAN)
- Continue immunotherapy as maintenance

**Alternative (if immunotherapy contraindicated):**
- Platinum + etoposide alone

**Thoracic Radiation:**
- Consider consolidative thoracic RT for residual thoracic disease

**PCI:**
- Discuss with patient; surveillance MRI alternative

### Relapsed/Refractory
**Sensitive Relapse (â‰¥3 months from prior therapy):**
- Topotecan (oral or IV)
- Lurbinectedin
- Re-challenge with platinum/etoposide

**Refractory (<3 months):**
- Clinical trial preferred
- Topotecan, lurbinectedin, or other single-agent therapy
- Best supportive care

### T-Cell Engager Therapy
- Tarlatamab (DLL3-targeting bispecific) for relapsed SCLC

### Surveillance
- CT scan every 2-3 months initially
- Brain MRI if not on PCI
